{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:47:29Z","timestamp":1787510849319,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.numecd.2021.07.015","type":"journal-article","created":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T10:50:20Z","timestamp":1627123820000},"page":"3193-3201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus"],"prefix":"10.1016","volume":"31","author":[{"given":"Valentina","family":"Guarnotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Vigneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Panto\u2019","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Lo Sasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Ciaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6052-8438","authenticated-orcid":false,"given":"Giuseppe","family":"Pizzolanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1731-9395","authenticated-orcid":false,"given":"Carla","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2021.07.015_bib1","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1001\/jama.291.21.2616","article-title":"The global burden of chronic diseases: overcoming impediments to prevention and control","volume":"291","author":"Yach","year":"2004","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.numecd.2021.07.015_bib2","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/jcb.25077","article-title":"The implications of sarcopenia and sarcopenic obesity on cardiometabolic disease","volume":"116","author":"Kim","year":"2015","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.numecd.2021.07.015_bib3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3904\/kjim.2016.193","article-title":"Sarcopenia and sarcopenic obesity","volume":"31","author":"Choi","year":"2016","journal-title":"Korean J Intern Med (Engl Ed)"},{"key":"10.1016\/j.numecd.2021.07.015_bib4","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2147\/DMSO.S249090","article-title":"Circulating irisin levels as a marker of osteosarcopenic-obesity in cushing's disease","volume":"13","author":"Guarnotta","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.numecd.2021.07.015_bib5","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.numecd.2007.10.002","article-title":"Sarcopenic obesity: a new category of obesity in the elderly","volume":"18","author":"Zamboni","year":"2008","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2021.07.015_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1146\/annurev-immunol-031210-101322","article-title":"Inflammatory mechanisms in obesity","volume":"29","author":"Gregor","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.numecd.2021.07.015_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115407","article-title":"Impact of visceral fat on skeletal muscle mass and vice versa in a prospective cohort study: the Korean sarcopenic Obesity Study (KSOS)","volume":"9","author":"Kim","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.numecd.2021.07.015_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3803\/EnM.2016.31.1.1","article-title":"The impact of organokines on insulin resistance, inflammation, and atherosclerosis","volume":"31","author":"Choi","year":"2016","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.numecd.2021.07.015_bib9","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.2174\/0929867325666171205144627","article-title":"Adipokines and myokines: a pivotal role in metabolic and cardiovascular disorders","volume":"25","author":"Chung","year":"2018","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.numecd.2021.07.015_bib10","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1210\/jc.2015-1208","article-title":"Irisin and its relation to insulin resistance and puberty in obese children: a longitudinal analysis","volume":"100","author":"Reinehr","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2021.07.015_bib11","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1210\/jc.2013-2373","article-title":"Circulating irisin in relation to insulin resistance and the metabolic syndrome","volume":"98","author":"Park","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2021.07.015_bib12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.diabres.2013.01.007","article-title":"Serum irisin levels in new-onset type 2 diabetes","volume":"100","author":"Choi","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.numecd.2021.07.015_bib13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jdiacomp.2013.03.002","article-title":"Lower circulating irisin is associated with type 2 diabetes mellitus","volume":"27","author":"Liu","year":"2013","journal-title":"J Diabet Complicat"},{"issue":"1","key":"10.1016\/j.numecd.2021.07.015_bib14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/1753-0407.12256","article-title":"Lower irisin level in patients with type 2 diabetes mellitus: a case-control study and meta-analysis","volume":"8","author":"Zhang","year":"2016","journal-title":"J Diabetes"},{"key":"10.1016\/j.numecd.2021.07.015_bib15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.atherosclerosis.2013.08.036","article-title":"Impact of inflammatory biomarkers on relation of high density lipoprotein-cholesterol with incident coronary heart disease: cardiovascular Health Study","volume":"231","author":"Tehrani","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2021.07.015_bib16","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.atherosclerosis.2008.07.031","article-title":"Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT)","volume":"203","author":"Saremi","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2021.07.015_bib17","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2021.07.015_bib18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tem.2016.10.001","article-title":"Glucagon-like peptide-1 and the central\/peripheral nervous system: crosstalk in diabetes","volume":"28","author":"Muscogiuri","year":"2017","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.numecd.2021.07.015_bib19","first-page":"157201","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis","author":"Sun","year":"2015","journal-title":"Journal of Diabetes Research"},{"key":"10.1016\/j.numecd.2021.07.015_bib20","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/eurheartj\/ehaa082","article-title":"Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials","volume":"41","author":"Marsico","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2021.07.015_bib21","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/jcb.24425","article-title":"Exendin-4 inhibits iNOS expression at the protein level in LPS-stimulated Raw264.7 macrophage by the activation of cAMP\/PKA pathway","volume":"114","author":"Chang","year":"2013","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.numecd.2021.07.015_bib22","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc20-S002","article-title":"Classification and diagnosis of diabetes: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2021.07.015_bib23","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","year":"2001","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.numecd.2021.07.015_bib24","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/dc09-1825","article-title":"Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk","volume":"33","author":"Amato","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2021.07.015_bib25","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cmet.2013.12.017","article-title":"Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans","volume":"19","author":"Lee","year":"2014","journal-title":"Cell Metabol"},{"key":"10.1016\/j.numecd.2021.07.015_bib26","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.2147\/DMSO.S216054","article-title":"Long-acting injectable GLP-1 receptor agonists for the treatment of adults with type 2 diabetes: perspectives from clinical practice","volume":"13","author":"Morieri","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.numecd.2021.07.015_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1476-511X-14-2","article-title":"Irisin: a new molecular marker and target in metabolic disorder","volume":"14","author":"Chen","year":"2015","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.numecd.2021.07.015_bib28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nrendo.2016.221","article-title":"Physiology and role of irisin in glucose homeostasis","volume":"13","author":"Perakakis","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.numecd.2021.07.015_bib29","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1042\/CS20150009","article-title":"Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K\/Akt pathway in type 2 diabetic mice and hepatocytes","volume":"129","author":"Liu","year":"2015","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.numecd.2021.07.015_bib30","first-page":"235","article-title":"A review on the role of irisin in insulin resistance and type 2 diabetes mellitus","volume":"20","author":"Gizaw","year":"2017","journal-title":"J Pharmacopuncture"},{"key":"10.1016\/j.numecd.2021.07.015_bib31","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2337\/db13-1106","article-title":"Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signalling","volume":"63","author":"Zhang","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2021.07.015_bib32","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cell.2013.04.008","article-title":"Betatrophin: a hormone that controls pancreatic \u03b2 cell proliferation","volume":"153","author":"Yi","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.numecd.2021.07.015_bib33","first-page":"6490","article-title":"Decreased irisin secretion contributes to muscle insulin resistance in high-fat diet mice","volume":"8","author":"Yang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.numecd.2021.07.015_bib34","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.jdiacomp.2016.07.020","article-title":"Exenatide treatment increases serum irisin levels in patients with obesity and newly diagnosed type 2 diabetes","volume":"30","author":"Liu","year":"2016","journal-title":"J Diabet Complicat"},{"key":"10.1016\/j.numecd.2021.07.015_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154319","article-title":"Circulating irisin concentrations are associated with a favourable lipid profile in the general population","volume":"11","author":"Oelmann","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.numecd.2021.07.015_bib36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/08830189809042997","article-title":"Interleukin 6 and its receptor: ten years later","volume":"16","author":"Hirano","year":"1998","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.numecd.2021.07.015_bib37","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.2337\/diabetes.54.suppl_2.S114","article-title":"Interleukin-6 and diabetes: the good, the bad, or the indifferent?","volume":"54","author":"Kristiansen","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2021.07.015_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cytogfr.2016.10.003","article-title":"Myokines and adipokines: involvement in the crosstalk between skeletal muscle and adipose tissue","volume":"33","author":"Li","year":"2017","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.numecd.2021.07.015_bib39","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2337\/diabetes.52.3.812","article-title":"Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study","volume":"52","author":"Spranger","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2021.07.015_bib40","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/db12-1625","article-title":"Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study","volume":"63","author":"Lowe","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2021.07.015_bib41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2017.06.008","article-title":"Repeated measurements of serum concentrations of TNF-alpha, interleukin-6 and interleukin-10 in the evaluation of internal carotid artery stenosis progression","volume":"263","author":"Puz","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2021.07.015_bib42","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1464-5491.1992.tb01898.x","article-title":"Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses at various stages of diabetic neuropathy","volume":"9","author":"Ziegler","year":"1992","journal-title":"Diabet Med"},{"key":"10.1016\/j.numecd.2021.07.015_bib43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to Interleukin-6 to Interleukin-1: moving upstream to identify novel targets for Atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.numecd.2021.07.015_bib44","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.ATV.0000073313.16135.21","article-title":"Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients","volume":"23","author":"Kopp","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2021.07.015_bib45","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/dom.12884","article-title":"Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial","volume":"19","author":"von Scholten","year":"2017","journal-title":"Diabetes Obes Metabol"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475321003367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475321003367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:19:46Z","timestamp":1760545186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475321003367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0939475321003367"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2021.07.015","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2021.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}